Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel…
Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, announced a multi-year…
Read More...
Read More...
